Cooperating gene mutations in acute myeloid leukemia: a review of the literature - PubMed (original) (raw)
Review
doi: 10.1038/leu.2008.19. Epub 2008 Feb 21.
Affiliations
- PMID: 18288131
- DOI: 10.1038/leu.2008.19
Review
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
A Renneville et al. Leukemia. 2008 May.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic disorders with great variability in clinical course and response to therapy, as well as in the genetic and molecular basis of the pathology. Major advances in the understanding of leukemogenesis have been made by the characterization and the study of acquired cytogenetic abnormalities, particularly reciprocal translocations observed in AML. Besides these major cytogenetic abnormalities, gene mutations also constitute key events in AML pathogenesis. In this review, we describe the contribution of known gene mutations to the understanding of AML pathogenesis and their clinical significance. To gain more insight in this understanding, we clustered these alterations in three groups: (1) mutations affecting genes that contribute to cell proliferation (FLT3, c-KIT, RAS, protein tyrosine standard phosphatase nonreceptor 11); (2) mutations affecting genes involved in myeloid differentiation (AML1 and CEBPA) and (3) mutations affecting genes implicated in cell cycle regulation or apoptosis (P53, NPM1). This nonexhaustive review aims to show how gene mutations interact with each other, how they contribute to refine prognosis and how they can be useful for risk-adapted therapeutic management of AML patients.
Similar articles
- Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Schlenk RF, et al. N Engl J Med. 2008 May 1;358(18):1909-18. doi: 10.1056/NEJMoa074306. N Engl J Med. 2008. PMID: 18450602 - Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Green CL, et al. J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439648 - Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T. Bienz M, et al. Clin Cancer Res. 2005 Feb 15;11(4):1416-24. doi: 10.1158/1078-0432.CCR-04-1552. Clin Cancer Res. 2005. PMID: 15746041 - Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD, Bullinger L. Baldus CD, et al. Semin Oncol. 2008 Aug;35(4):356-64. doi: 10.1053/j.seminoncol.2008.04.006. Semin Oncol. 2008. PMID: 18692686 Review. - Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Pedersen-Bjergaard J, et al. Leukemia. 2006 Nov;20(11):1943-9. doi: 10.1038/sj.leu.2404381. Epub 2006 Sep 21. Leukemia. 2006. PMID: 16990778 Review.
Cited by
- Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature.
Cauchy P, James SR, Zacarias-Cabeza J, Ptasinska A, Imperato MR, Assi SA, Piper J, Canestraro M, Hoogenkamp M, Raghavan M, Loke J, Akiki S, Clokie SJ, Richards SJ, Westhead DR, Griffiths MJ, Ott S, Bonifer C, Cockerill PN. Cauchy P, et al. Cell Rep. 2015 Aug 4;12(5):821-36. doi: 10.1016/j.celrep.2015.06.069. Epub 2015 Jul 23. Cell Rep. 2015. PMID: 26212328 Free PMC article. - High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia.
Yin JY, Tang Q, Zhai LL, Zhou LY, Qian J, Lin J, Wen XM, Zhou JD, Zhang YY, Zhu XW, Deng ZQ. Yin JY, et al. Tumour Biol. 2015 Dec;36(12):9711-6. doi: 10.1007/s13277-015-3731-5. Epub 2015 Jul 9. Tumour Biol. 2015. PMID: 26152287 - MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders.
Yuan Y, Kasar S, Underbayev C, Prakash S, Raveche E. Yuan Y, et al. Leuk Res Treatment. 2012;2012:603830. doi: 10.1155/2012/603830. Epub 2012 Jun 17. Leuk Res Treatment. 2012. PMID: 23259069 Free PMC article. - Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S. Pollard JA, et al. Blood. 2010 Mar 25;115(12):2372-9. doi: 10.1182/blood-2009-09-241075. Epub 2010 Jan 7. Blood. 2010. PMID: 20056794 Free PMC article. - Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, Mohammad HP, Ye Y, Herman JG, Carraway HE. Griffiths EA, et al. Leuk Lymphoma. 2010 Sep;51(9):1711-9. doi: 10.3109/10428194.2010.496505. Leuk Lymphoma. 2010. PMID: 20795789 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous